BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cava C, Bertoli G, Castiglioni I. In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition. J Transl Med 2018;16:154. [PMID: 29871693 DOI: 10.1186/s12967-018-1535-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Flashner-Abramson E, Vasudevan S, Adejumobi IA, Sonnenblick A, Kravchenko-Balasha N. Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy. Theranostics 2019;9:5149-65. [PMID: 31410207 DOI: 10.7150/thno.31657] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
2 Cova TFGG, Bento DJ, Nunes SCC. Computational Approaches in Theranostics: Mining and Predicting Cancer Data. Pharmaceutics 2019;11:E119. [PMID: 30871264 DOI: 10.3390/pharmaceutics11030119] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
3 Rausch M, Weiss A, Achkhanian J, Rotari A, Nowak-Sliwinska P. Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma. Br J Cancer 2020;123:556-67. [PMID: 32439932 DOI: 10.1038/s41416-020-0890-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
4 Cava C, Sabetian S, Castiglioni I. Patient-Specific Network for Personalized Breast Cancer Therapy with Multi-Omics Data. Entropy (Basel) 2021;23:225. [PMID: 33670375 DOI: 10.3390/e23020225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cava C, Bertoli G, Castiglioni I. In Silico Discovery of Candidate Drugs against Covid-19. Viruses 2020;12:E404. [PMID: 32268515 DOI: 10.3390/v12040404] [Cited by in Crossref: 87] [Cited by in F6Publishing: 61] [Article Influence: 43.5] [Reference Citation Analysis]
6 Emmert-streib F, Dehmer M. Inference of Genome-Scale Gene Regulatory Networks: Are There Differences in Biological and Clinical Validations? MAKE 2018;1:138-48. [DOI: 10.3390/make1010008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
7 Mehdizadehtapeh L, Obakan Yerlİkaya P. Endoplasmic reticulum stress and oncomir-associated chemotherapeutic drug resistance mechanisms in breast cancer tumors. Turk J Biol 2021;45:1-16. [PMID: 33597817 DOI: 10.3906/biy-2010-62] [Reference Citation Analysis]
8 Proschak E, Stark H, Merk D. Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. J Med Chem 2019;62:420-44. [PMID: 30035545 DOI: 10.1021/acs.jmedchem.8b00760] [Cited by in Crossref: 144] [Cited by in F6Publishing: 119] [Article Influence: 36.0] [Reference Citation Analysis]
9 Cava C, Castiglioni I. In silico perturbation of drug targets in pan-cancer analysis combining multiple networks and pathways. Gene 2019;698:100-6. [PMID: 30840853 DOI: 10.1016/j.gene.2019.02.064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cava C, Bertoli G, Castiglioni I. A protein interaction map identifies existing drugs targeting SARS-CoV-2. BMC Pharmacol Toxicol 2020;21:65. [PMID: 32883368 DOI: 10.1186/s40360-020-00444-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
11 Agamah FE, Mazandu GK, Hassan R, Bope CD, Thomford NE, Ghansah A, Chimusa ER. Computational/in silico methods in drug target and lead prediction. Brief Bioinform 2020;21:1663-75. [PMID: 31711157 DOI: 10.1093/bib/bbz103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
12 Tan YJ, Lee YT, Mancera RL, Oon CE. BZD9L1 sirtuin inhibitor: Identification of key molecular targets and their biological functions in HCT 116 colorectal cancer cells. Life Sci 2021;:119747. [PMID: 34171380 DOI: 10.1016/j.lfs.2021.119747] [Reference Citation Analysis]
13 Cava C, Pini S, Taramelli D, Castiglioni I. Perturbations of pathway co-expression network identify a core network in metastatic breast cancer. Comput Biol Chem 2020;87:107313. [PMID: 32590221 DOI: 10.1016/j.compbiolchem.2020.107313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Rausch M, Rutz A, Allard PM, Delucinge-Vivier C, Docquier M, Dormond O, Wolfender JL, Nowak-Sliwinska P. Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells. Int J Mol Sci 2021;22:6467. [PMID: 34208775 DOI: 10.3390/ijms22126467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Al-Taie Z, Hannink M, Mitchem J, Papageorgiou C, Shyu CR. Drug Repositioning and Subgroup Discovery for Precision Medicine Implementation in Triple Negative Breast Cancer. Cancers (Basel) 2021;13:6278. [PMID: 34944904 DOI: 10.3390/cancers13246278] [Reference Citation Analysis]
16 Gao D, Chen Q, Zeng Y, Jiang M, Zhang Y. Applications of Machine Learning in Drug Target Discovery. Curr Drug Metab 2020;21:790-803. [PMID: 32723266 DOI: 10.2174/1567201817999200728142023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Cava C, Pisati M, Frasca M, Castiglioni I. Identification of Breast Cancer Subtype-Specific Biomarkers by Integrating Copy Number Alterations and Gene Expression Profiles. Medicina (Kaunas) 2021;57:261. [PMID: 33809336 DOI: 10.3390/medicina57030261] [Reference Citation Analysis]